Further analysis of endogenous BMPR2 mutant product folding and signaling defects in HPAH patients carrying different NMD negative BMPR2 mutations will have to be performed to determine which patients might benefit from this therapy. Here, BMPR2 is linked to heritable pulmonary arterial hypertension.